What Is the First-Line Treatment for Acute Toxoplasmosis?
Acute toxoplasmosis (ICD-10 B58.9 / ICD-11 1F57.Z) requires structured combination treatment. The standard first-line regimen pairs a primary agent with bone marrow support, and incorporates a second drug selected according to patient-specific tolerability.
Treatment Approach
First-line management centers on pyrimethamine as the primary agent, combined with folinic acid (leucovorin) to counteract bone marrow effects associated with pyrimethamine. A second complementary agent is added, with the choice guided by individual patient factors such as drug tolerability.
Full regimen details — including agent selection, dosing, and sequencing — are available in the complete structured protocol below.
References
- Pyrimethamine, considered the most effective drug against toxoplasmosis, is a standard component of therapy.
- Pyrimethamine is a folic acid antagonist and can cause dose-related suppression of the bone marrow, which is mitigated by concurrent administration of folinic acid (leucovorin).
- Leucovorin protects the bone marrow from the toxic effects of pyrimethamine.
- A second drug, such as sulfadiazine or clindamycin (if the patient has a hypersensitivity reaction to sulfa drugs), should also be included.
View source ↗